University of Wollongong

Research Online
Illawarra Health and Medical Research Institute

Faculty of Science, Medicine and Health

2013

Teasaponin reduces inflammation and central
leptin resistance in diet-induced obese male mice
Yinghua Yu
University of Wollongong, yinghua@uow.edu.au

Yizhen Wu
University of Wollongong, yw903@uowmail.edu.au

Alexander Szabo
University of Wollongong, aszabo@uow.edu.au

Zhixiang Wu
University of Wollongong, zwu@uow.edu.au

Hongqin Wang
University of Wollongong, hongqin@uow.edu.au
See next page for additional authors

Publication Details
Yu, Y., Wu, Y., Szabo, A., Wu, Z., Wang, H., Li, D. & Huang, X. (2013). Teasaponin reduces inflammation and central leptin resistance
in diet-induced obese male mice. Endocrinology, 154 (9), 3130-3140.

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au

Teasaponin reduces inflammation and central leptin resistance in dietinduced obese male mice
Abstract

Chronic inflammation is involved in the pathogenesis of obesity and type 2 diabetes. Recently, teasaponin, an
extract from tea, has been shown to have anti-inflammatory effects. We examined the effect of teasaponin on
obesity, inflammation, glucose metabolism and central leptin sensitivity, in obese mice fed a high-fat (HF)
diet for 16 weeks. Intraperitoneal injections of teasaponin (10mg/kg, daily) for 21 days significantly decreased
the food intake and body weight of HF diet-induced obese mice. Teasaponin treatment also reduced the
protein levels of pro-inflammatory cytokines (TNF-α, IL-6 and/or IL-1β) and NF-κB signaling (p-IKK and pIκBα) in adipose tissue and the liver. The anti-inflammatory effects of teasaponin were associated with
improved glycemic status in the treated animals, evidenced by improved glucose tolerance, homeostasis
model assessment (HOMA) and fasting plasma insulin. In the hypothalamus teasaponin decreased both proinflammatory cytokines and inflammatory signaling in the mediobasal hypothalamus. Teasaponin treatment
also enhanced the anorexigenic effect of central leptin administration, restored leptin p-STAT3 signaling in
the Arc, and increased hypothalamic expression of the anorexigenic peptide proopiomelanocortin (POMC).
These results identify a potential novel application for teasaponin as an anti-obesity and anti-inflammatory
agent.
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Teasaponin reduces inflammation and central leptin
resistance in diet-induced obese male mice
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Chronic inflammation is involved in the pathogenesis of obesity and type 2 diabetes. Recently,
teasaponin, an extract from tea, has been shown to have anti-inflammatory effects. We examined
the effect of teasaponin on obesity, inflammation, glucose metabolism and central leptin sensitivity, in obese mice fed a high-fat (HF) diet for 16 weeks. Intraperitoneal injections of teasaponin
(10mg/kg, daily) for 21 days significantly decreased the food intake and body weight of HF dietinduced obese mice. Teasaponin treatment also reduced the protein levels of pro-inflammatory
cytokines (TNF-␣, IL-6 and/or IL-1␤) and NF-B signaling (p-IKK and p-IB␣) in adipose tissue and the
liver. The anti-inflammatory effects of teasaponin were associated with improved glycemic status
in the treated animals, evidenced by improved glucose tolerance, homeostasis model assessment
(HOMA) and fasting plasma insulin. In the hypothalamus teasaponin decreased both pro-inflammatory cytokines and inflammatory signaling in the mediobasal hypothalamus. Teasaponin treatment also enhanced the anorexigenic effect of central leptin administration, restored leptin pSTAT3 signaling in the Arc, and increased hypothalamic expression of the anorexigenic peptide
proopiomelanocortin (POMC). These results identify a potential novel application for teasaponin
as an anti-obesity and anti-inflammatory agent.

besity has reached epidemic proportions and is an
important risk factor for the development of type 2
diabetes, cardiovascular disease, and some forms of cancer. There is compelling evidence that a large component
of obesity-associated pathophysiology may stem from the
low-grade inflammation that occurs during obesity. This
includes increased production of proinflammatory cytokines such as tumor necrosis factor (TNF) alpha (TNF-␣),
interleukin 1 beta (IL-1␤) and interleukin 6 (IL-6), and
activation of the nuclear factor -light-chain-enhancer of
activated B cells (NF-B) inflammatory signaling pathway
in adipose tissue, liver and the hypothalamus of the brain
(1, 2).
Overnutrition induces inflammatory responses in pe-

O

ripheral metabolic tissues, including the infiltration of
proinflammatory cytokine secreting macrophages into the
adipose tissue of obese mice and humans (1, 3, 4). Proinflammatory cytokines decrease insulin sensitivity in insulin target cells (adipocytes, hepatocytes and myocytes) and
contribute to systemic insulin resistance, glucose intolerance and the development of type 2 diabetes. In obese
rodents fed a high-fat (HF) diet, macrophages also infiltrate the liver and increase the mRNA expression of the
proinflammatory cytokines TNF-␣, IL-1␤ and IL-6 (5, 6).
Inflammatory cytokines released by liver macrophages
can activate the NF-B signaling pathway in hepatocytes,
causing hepatic insulin resistance (1, 6). Recent research
has identified a similar type of low-grade inflammation in
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Anti-inflammatory effect of teasaponin in diet-induced obese mice

the hypothalamus of rodents (2), where TNF-␣, IL-6 and
IB kinase (IKK) mRNA expression are increased within
a week of starting a HF diet. IKK along with inhibitor
kappa B alpha (IB␣) are components of the NF-B signaling pathway, and commonly used to investigate inflammatory signaling events. Hypothalamic inflammation results in central leptin resistance, hepatic insulin
resistance, a reduction in thermogenesis and cardiovascular disorders (7). Therefore, blocking the peripheral and
central inflammation induced by HF diet has the potential
to treat obesity and metabolic syndrome. This could be
achieved using novel therapies incorporating effective natural agents, particularly agents with the dual properties of
preventing inflammation and controlling body weight.
From ancient times tea has been widely used as a
healthy drink worldwide. Recent evidence has emerged
that tea can prevent obesity and abnormal glucose and
lipid metabolism (8, 9). The earliest use of tea for medicinal purposes occurred in China, in roughly 2700 BC during the time of Emperor Shen Nung (10). During that time,
it was believed to have health promoting properties, and
was frequently used as a fluid supply for patients with
infectious diseases. Recently, the effect of tea on inflammation has received increasing attention. Six cups of green
tea daily for three to eight weeks significantly reduced
NF-B signaling in men with prostate cancer prior to undergoing prostatectomy, compared to the control group
(11). Treatment of genetically obese (ob/ob) mice with 1%
tea extract in diet for 6 wk decreased hepatic TNF-␣ protein, adipose TNF-␣ mRNA, and attenuated hepatic steatosis (12). Furthermore, supplementation of HF diet with
tea extract significantly reduced HF diet induced p-IB␣
and NF-B activity in liver and adipose tissue (13). Phenolics and saponin are the two major active components
of tea extract. Phenolics in tea have been widely investigated in previous studies, while teasaponin (TS), an important bioactive ingredient of tea extract, has received
little attention. Teasaponin chemically, belongs to the
oleanane-type pentacyclic triterpene saponins, which are
naturally derived inhibitors of NF-kB signaling and have
anti-inflammatory potential (14). Recently teasaponin (10
mg/kg ip injection) showed significant anti-inflammatory
properties, by inhibiting paw edema induced by carrangeenan in rats (15). In this study, we investigated
whether chronic treatment with teasaponin could reduce
inflammation in the hypothalamus and peripheral tissues,
and therefore improve blood glucose control and central
leptin sensitivity in HF diet-induced obese mice.

Endocrinology

tre (Perth, Western Australia). The mice were housed in environmentally controlled conditions (temperature 22°C, 12 h
light/dark cycle). Lab chow served as the low-fat (LF) control diet
(5% fat, Vella Stock Feeds, Doonside, NSW, Australia) and was
provided ad libitum except where noted. All procedures were
approved by the Animal Ethics Committee, University of Wollongong, Australia, and complied with the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes.

Teasaponin treatment of high-fat diet-induced
obese mice
Mice were fed standard laboratory chow for the first week to
allow them to adapt to their new environment, and then placed
on a high-fat (HF) diet containing 40% fat by calories (SF11–
095; Specialty Feeds, Western Australia) for 16 wk. After this
feeding period the mice were obese (mean body weight 44.18 ⫾
2.60g). The animals were then randomized into two groups, with
either teasaponin (TS, 10 mg/kg) or vehicle (saline) administered
daily via intraperitoneal (ip) injection for 21 d (chronic treatment
of teasaponin). Food intake and body weight were recorded
daily. Also included in this study were low-fat (LF) diet control
mice, which were age-matched, maintained on the LF control
diet, and not treated with TS. Teasaponin (96%, C57H90O26,
MW ⫽ 1200) was purchased from the Aladdin Chemistry Co.
Ltd, China.
Blood glucose tolerance tests were performed on day 18 of
teasaponin treatment. The cannula implantation surgery was
performed following 21 d of TS treatment. After a 5 d recovery
from surgery, the first icv administration of leptin (or saline) was
performed for the central leptin sensitivity test (detailed below).
Following a 4 d interval, the mice received the second icv leptin
injection and were sacrificed one hour later to collect tissues as
in the previous study (16). Plasma, white adipose tissue, liver and
brain tissue were collected and stored at – 80°C for further analyses as detailed below.
Similar to the previous study (17), the frozen brain sections
containing the arcuate nucleus were cut at 500 m ranging from
Bregma –1.22 mm to –2.72 mm based on a standard mouse brain
atlas (18), using a cryostat with the temperature set at –18°C. The
arcuate nucleus was dissected and then collected using a Stoelting
Brain Punch (#57401, 0.5 mm diameter, Wood Dale, Stoelting
Co, USA) in an overlapping pattern over the third ventricle. The
punched tissue principally contained arcuate nucleus, but we
cannot rule out the inclusion of adjacent brain areas. Therefore,
the punched tissue was named as the mediobasal hypothalamus.

Intraperitoneal glucose tolerance test
On day 18 of the teasaponin treatment, the mice fasted overnight and were given an ip injection of glucose (0.5g/kg). Blood
samples were taken from the tail vein, and glucose was measured
using a glucometer (Freestyle; Abbott Diabetes Care, Alameda,
CA) at 0 (fasting), 30, 60 and 120 min after glucose
administration.

Central leptin sensitivity tests

Materials and Methods
Animals
Animals: C57Bl/6J male mice (10 wk old, body weight:
19.62 ⫾ 1.40g) were obtained from the Animal Resources Cen-

The central leptin sensitivity was examined in moderate and
severely obese mice. For moderate obesity, mice were fed a highfat diet for 8 wk followed by an acute treatment of teasaponin (10
mg/kg/day, ip) for 2 d. For severe obesity, the mice were fed a
high-fat diet for 16 wk followed by a chronic treatment of teasa-
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ponin (10 mg/kg/day, ip) for 21 d. Animals were maintained on
a high-fat diet during both acute and chronic teasaponin treatment. The central leptin sensitivity test was performed as follows. Mice were anesthetized by isoflurane inhalation and placed
in a stereotactic device. An intracerebroventricular (icv) cannula
was implanted into the right lateral brain ventricle (0.25 mm
posterior and 1.0 mm lateral relative to Bregma and 2.5 mm
below the surface of the skull) (18). Five days after implantation,
the mice fasted for 6 h. Either leptin (0.1 g/3 l) or saline (3 l)
was then injected into the lateral ventricle through the cannula.
Food intake was measured at 1, 4 and 24 h, and body weight was
measured 24 h after the leptin or vehicle injection. The accuracy
of cannula implantation into the lateral ventricle was confirmed
by examining the needle track on the brain sections of each
animal.

Conditioned taste aversion
We used a standard two-bottle preference paradigm (19, 20).
Mice were adapted to 2 h daily access to water (available in two
bottles) for 10 d. On day 11, the mice were given 0.15% saccharin in water in each bottle for the 2 h period instead of water,
and then injected with either teasaponin (10 mg/kg, ip), vehicle
(saline 0.3 ml, ip), or LiCl as a positive control (0.15 mol/l; 2
mmol/kg ip) (n ⫽ 8). On days 12–13, the animals had water in
both bottles, and on the test day (day 14), the mice were given one
bottle containing saccharin and one containing water. The saccharin preference ratio was calculated as the amount of saccharin
consumed divided by the total consumption of both liquids over
2 h.

Measurement of plasma leptin, insulin,
adiponectin, peptide YY (PYY) and monocyte
chemoattractant protein (MCP-1)
Plasma leptin, insulin, PYY, and MCP-1 were measured using
the mouse metabolic magnetic bead panel kit and adiponectin
was determined with the mouse single plex adiponectin kit
(Merck Millipore, MA, USA). The homeostasis model assessment (HOMA) of insulin sensitivity was calculated using the
following formula: (fasting glucose [mmol/l] multiplied by fasting insulin [U/ml] divided by 22.5) (21).

Histological analysis and morphometry
Epididymal adipose tissue was fixed in 10% buffered formaldehyde and embedded in paraffin. Tissue sections (5 m) were
cut and mounted onto polysine slides. The sections were stained
with hematoxylin and eosin and photographed at 100⫻ magnification. Using the software Image J 1.46r (http://rsbweb.nih.gov/ij/download.html) two fields per section and six sections per
fat mass were analyzed to quantify the area and number of
adipocytes.

Western blot analysis
As described in our previous study (22), for protein extraction
the frozen tissues were homogenized in a NP-40 lysis buffer. The
following antibodies were used: TNF-␣ (sc-8301), IL-1␤ (sc7884) and IL-6 (sc-7920) from Santa Cruz Biotechnology, and
p-IKK (Ser176/180) (#2697), p-IB␣ (Ser32) (#2859), p-STAT3
(Tyr705) (#9145) and SOCS3 (#2932) from Cell Signaling Technology (Beverly, MA). The bands corresponding to the proteins
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of interest were scanned and band density analyzed using the
automatic imaging analysis system, Quantity One (BioRad). All
quantitative analyses were normalized to ␤-actin, based on our
previous studies (22). Due to the small amount of tissue in the
mediobasal hypothalamus, we used a previously described modified multistrip western blot (23), which allows the detection of
multiple proteins with a smaller sample size than standard western blot (see supplementary figure 1 for details).

qPCR for neuropeptide mRNA measurement
Total mediobasal hypothalamic RNA was extracted using the
Aurum total RNA mini kit (Bio-Rad Laboratories, Hercules,
CA) and reverse-transcribed to first-strand complementary
DNA (cDNA) with the high-capacity cDNA reverse transcription kit (AB Applied Biosystems, California, USA) according to
the manufacturer’s instructions. Quantitative real-time PCR
(qPCR) was performed in a 20 l final reaction volume using
SYBR green I master in a Lightcycler 480 (F. Hoffmann-La
Roche Ltd, Switzerland). Primers used are listed in supplemental
Table 1. Amplification was carried out with 45 cycles of 95°C for
10 s, 60°C for 30 s and 72°C for 30 s. mRNA expression levels
for neuropeptides were normalized to gamma actin, which
served as the internal control. Experiments were performed in
triplicate. The level of expression for each gene was calculated
using the comparative threshold cycle value (Ct) method, using
the formula 2–⌬⌬Ct (where ⌬⌬Ct ⫽⌬Ct sample - ⌬Ct reference)
as described previously (24, 25).

Statistical analysis
Data were analyzed using the SPSS 19 statistical package
(SPSS, Chicago, IL, USA). Two-way repeated-measure ANOVA
followed by two-tailed student’s t-tests were used to analyze
body weight and food intake during the teasaponin treatment.
Two-tailed student’s t-tests were used to analyze adipose tissue
histology and weight, and liver weight between the teasaponin
treatment and vehicle groups. One-way analysis of variance
(ANOVA) followed by the post hoc Tukey–Kramer honestly
significant difference (HSD) test was used to analyze the conditioned taste aversion assessment, plasma cytokines, hypothalamic neuropeptides and central leptin sensitivity test. A p value
of less than 0.05 was regarded as statistically significant, and p
values of less than 0.10 were considered a trend. Values are
expressed as mean ⫾ SEM.

Results
Teasaponin reduced body weight and food intake
in obese mice
When teasaponin was administrated via ip injection to
HF diet-induced obese mice it significantly reduced body
weight and food intake during the 21-d observation period
(Figures 1A and 1B). The body weight and food intake
during the teasaponin treatment were significantly affected by the treatment, week factors and their interaction
(supplementary Table 2). The final body weight and average energy intake of the teasaponin group was also significantly lower than the HF control group following
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Figure 1. Chronic administration of teasaponin (TS, 10 mg/kg ip for
21 d) significantly decreased body weight (A), daily food intake (B) and
average energy intake (C) in obese mice (n ⫽ 16) fed a high-fat (HF)
diet for 16 wk. *P ⬍ .05 vs. HF control group. Panel D: Conditioned
taste aversion assessment. Intraperitoneal administration of LiCl but
not teasaponin (10 mg/kg ip) caused a conditioned taste aversion
assessment in mice. Values are expressed as mean ⫾ SEM, n ⫽ 8.
**P ⬍ .001 vs. saline controls.
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Teasaponin reduced body fat and inflammation in
adipose tissue of obese mice
Consistent with reduced body weight, teasaponin also
significantly reduced body fat in HF diet-induced obese
mice compared with the control group (Figure 2A). Compared to the controls, teasaponin treated mice had significantly lower amounts of visceral and inguinal fat as a
percentage of body weight (Figure 2B). To determine
whether there was a region specific fat loss, selected fat
deposits were excised and weighed. The teasaponin treatment significantly decreased visceral fat, including epididymal, mesenteric and perirenal fat deposits compared with
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saccharin as the saline controls on the test day (Figure 1E),
indicating that malaise was not a factor in the suppressive
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Figure 2. Effect of chronic administration of teasaponin on body fat
in obese mice fed a high-fat (HF) diet for 16 wk. Body size (A), and
visceral fat and inguinal fat (B) were significantly decreased after TS
treatment (n ⫽ 8). Panel C: Photographs of epididymal and mesenteric
fat tissue. Panel D: Hematoxylin and eosin staining of epididymal fat
tissue, scale bar: 100 m. Panel E: Adipocyte area in epididymal fat
(n ⫽ 8). Panel F: Frequency distribution of adipocyte surface area in
epididymal fat (n ⫽ 8). Panel G: TS treatment significantly decreased
protein levels of the proinflammatory cytokines TNF-␣ and IL-I␤, as well
as the inflammatory signaling molecules p-IKK and p-IB␣, in the
epididymal fat of HF diet-induced obese mice (n ⫽ 8). *P ⬍ .05 vs. HF
control group.
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HF diet-induced mice than in the HF
controls (Figures 2D and 2E). The
distribution of adipocytes by cell surface area also showed a higher proportion of small sized cells (ⱕ1000
m2) in the teasaponin-treated HF
group than the HF control group
(Figure 2F). Finally, we found that
the teasaponin treatment significantly reduced the protein levels of
the proinflammatory cytokines
(TNF-␣ and IL-1␤), as well as the inflammatory signaling molecules (pIKK and p-IB␣), in the adipose tissue of HF diet-induced obese mice
(Figure 2G).
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Figure 3. Effect of chronic administration of teasaponin on liver appearance (A) and liver weight
steatotic than the livers from the con(B) and inflammatory markers (C) in the liver of obese mice (n ⫽ 8) fed a high-fat (HF) diet for 16
wk. Panel C: In the liver, chronic treatment of teasaponin significantly decreased the protein
trol HF diet-induced obese mice (Figlevels of the proinflammatory cytokines TNF-␣ and IL-6, as well as the inflammatory signaling
ures 3A and 3B). Teasaponin signifmolecules p-IKK and p-IB␣ in HF-induced obese mice. *P ⬍ .05 vs. HF diet control group.
icantly reduced the expression of
hepatic TNF-␣, IL-6, p-IKK and
the saline controls (Table 1, Figure 2C). Teasaponin affected the size of adipocytes, with adipocytes from visceral p-IB␣ protein in the HF diet-induced obese mice. Howfat pads being significantly smaller in teasaponin-treated ever, teasaponin did not significantly affect the expression
of hepatic IL-1␤ and SOCS3 in the same animals (Figure
3C).
Table 1. Weight of fat deposits and muscle in high-fat
(HF) diet-induced obese mice with or without teasaponin
Teasaponin improved glucose tolerance and blood
(TS) treatment.
hormone profiles
F
Glucose tolerance tests were performed to assess gluWeight
HF
HFⴙTS
value P value
cose homeostasis and insulin sensitivity in HF diet-inEpididymal fat (g) 1.90
1.01
51.650 ⬍0.001
duced obese mice treated with teasaponin. Blood glucose
⫾
⫾
levels were lower at the 30 and 60 min time points in the
0.10
0.06
teasaponin treatment group compared to the HF controls
Mesenteric fat (g) 0.83
0.45
30.922 ⬍0.001
during the glucose tolerance test (Figure 4A). The teasa⫾
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0.06
0.03
ponin treatment also decreased HOMA (Figure 4B), inPerirenal fat (g)
0.75
0.28
32.323 ⬍0.001
dicating that it reduced insulin resistance in the HF diet⫾
⫾
induced obese mice. HF diet-induced hyperinsulinemia
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0.03
and hyperleptinemia were significantly reversed by teasaVisceral fat (g)
3.49
1.69
50.678 ⬍0.001
⫾
⫾
ponin treatment (Figures 4C and 4D). In a statistical trend,
0.22
0.10
teasaponin also reduced hypoadiponectinemia in mice inInguinal fat (g)
1.28
0.49
40.275 ⬍0.001
duced by the HF diet (P ⫽ .076) (Figure 4E). Circulating
⫾
⫾
concentrations of the satiety peptide PYY significantly in0.12
0.03
Soleus muscle
21.31
19.50
3.449
0.072
creased in the teasaponin treatment group compared with
(mg)
⫾
⫾
the HF and LF mice (Figure 4F). There was no significant
0.77
0.60
difference in the plasma MCP-1 among the LF, HF and
Values are means ⫾SEM
teasaponin-treated HF groups (Figure 4G).
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HF-induced obese mice without
decreased plasma insulin (C) and leptin (D), and increased plasma adiponectin (E) and PYY (F), in
teasaponin treatment (P ⫽ .633; Figobese mice (n ⫽ 8) fed a high-fat (HF) diet for 16 wk. Panel G: MCP-1 levels in the plasma (n ⫽
8). *P ⬍ .05 vs. HF control group; ⫹P ⬍ .10 and ⬎ 0.05 vs. HF group; #P ⬍ .05 vs. low-fat (LF)
ure 7C), while energy intake was sigdiet control group. The homeostasis model assessment of insulin sensitivity (HOMA) is calculated
nificantly decreased in the teasapoby (fasting glucose [mmol/l] multiplied by fasting insulin [U/ml] divided by 22.5).
nin-treated mice receiving icv
injections of leptin compared with
Teasaponin increased the hypothalamic POMC
the icv injection of saline (-39%, P ⫽ .023; Figure 7C).
mRNA expression in obese mice
To clarify the mechanisms underlying the enhanced efThe effect of teasaponin on the expression of neuro- fect of leptin in the teasaponin-treated mice, we measured
peptides in the mediobasal hypothalamus was assessed to p-STAT3 protein levels in the mediobasal hypothalamus
investigate the mechanism by which teasaponin sup- after the chronic treatment with teasaponin and leptin
presses food intake. Chronic teasaponin treatment signif- stimulation. Leptin administered icv significantly inicantly increased hypothalamic anorexigenic POMC creased p-STAT3 in LF diet fed mice (P ⬍ .001; Figure 7D),
mRNA expression compared to the HF control mice (P ⫽ while p-STAT3 did not significantly increase in response
.026; Figure 5), but had no effect on orexigenic NPY and to the leptin injection in control HF diet-induced obese
AgRP mRNA levels.
mice (Figure 7E). With the teasaponin treatment, the p-

A

% NPY mRNA in HF mice % POMC mRNA in HF mice

doi: 10.1210/en.2013-1218

endo.endojournals.org

A

200

*

150

% AgRP mRNA in HF mice

100
50

140
120
100
80
60
40
20

120

LF
LF

HF
HF

HF+TS
TS

LF
LF

HF
HF

TS
HF+TS

B

C

100
80
60
40
20
0
LF
LF

HF
HF

HF+TS
TS

Figure 5. The effect of chronic teasaponin treatment on the
expression of the neuropeptide genes POMC (A), NPY (B) and AgRP (C)
in the mediobasal hypothalamus of obese mice (n ⫽ 6 – 8) fed a highfat (HF) diet for 16 wk. *P ⬍ .05 vs. HF group.

STAT3 level significantly increased after icv leptin injection compared with icv saline (94%, P ⬍ .001) (Figure 7E).

Discussion
This study demonstrated that teasaponin treatment reduced obesity, peripheral and hypothalamic inflammation, and central leptin resistance in high-fat (HF) dietinduced obese mice. Compared with the control obese
mice, the teasaponin treated obese mice had lower proinflammatory cytokines and signaling molecules in their visceral fat and liver. The anti-inflammatory effects of teasaponin were associated with an improved glycemic status in
the treated animals, evidenced by improved glucose tolerance, HOMA and fasting plasma insulin. Furthermore,
teasaponin decreased proinflammatory cytokines and inflammatory signaling in the mediobasal hypothalamus,
and enhanced the anorexigenic effect of central leptin ad-

7

ministration as demonstrated by the restoration of
p-STAT3 signaling in the mediobasal hypothalamus.
Chronic teasaponin treatment also suppressed energy intake and increased the expression of the anorexigenic neuropeptide POMC in the hypothalamus.
A low-grade proinflammatory state is at the pathogenic
core of obesity and its associated metabolic syndrome. We
have demonstrated for the first time that teasaponin (ip
injection) lowers proinflammatory cytokines (TNF-␣,
IL-6 and IL-1␤) in the adipose tissue of HF diet-induced
obese mice. Adiponectin is secreted from adipose tissue
and functions to reduce plasma glucose and fatty acid levels (26). Several studies have shown that obesity-associated inflammation can impair the production of adiponectin. For example, in vitro studies demonstrated that
TNF-␣ and/or IL-1␤ suppressed adiponectin expression in
human preadipocytes, adipose tissue and the 3T3-L1 cell
line (27–29). In a human study, it was found that adiponectin plasma levels and adipose-tissue gene expression
were significantly lower in obese subjects, and inversely
correlated with the inflammatory markers, IL-6 and highsensitive C-reactive protein (CRP) (30). In our study, the
teasaponin treatment was found to increase the level of
plasma adiponectin in HF mice, which may result from the
inhibition of the proinflammatory cytokine expression in
abdominal fat. The increase of plasma adiponectin after
teasaponin treatment may contribute to the antidiabetogenic effect observed in this study, as treatment with adiponectin has been found to improve insulin sensitivity in
obese mice (31).
The inflammatory signaling molecules p-IKK and
p-IB␣ were decreased in the adipose tissue and liver of
obese mice treated with teasaponin. The IKK/IB␣ complex mediates the activity of the NF-B transcription factor to regulate the expression of various cytokines. Activation
of
IKK
by
phosphorylation
induces
phosphorylation and degradation of its substrate, the inhibitory protein IB␣, which is normally bound to NFB.
The dissociation and degradation of IB␣ releases NFB
to translocate into the nucleus and mediate the transcription of various genes, including TNF-␣, IL-1␤ and IL-6
(32). Mice overexpressing IKK in their hepatocytes had an
increased hepatic production of IL-6, IL-1␤ and TNF-␣
(6). We have shown that teasaponin reduces the phosphorylation of IKK and IB␣ in the liver and adipose tissue, indicating that teasaponin inhibits proinflammatory
cytokines by suppressing NFB signaling upstream of
IKK/IB␣. The NF-B signaling pathway affects glucose
metabolism in multiple tissues (6, 33). For example, mice
overexpressing IKK in hepatocytes exhibit hyperglycemia,
profound hepatic insulin resistance and moderate systemic insulin resistance (6). Recently, IKK has been iden-
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in that an effective dose (ED) of
teasaponin did not cause a condi1.0
1
tioned taste aversion. Therefore, vis*
*
*
*
0.8
0.8
ceral illness is unlikely to be a factor
0.6
in the feeding suppressive actions of
0.6
0.4
peripherally administered teasapo0.4
nin. Importantly, this study found
0.2
0.2
that teasaponin treatment increased
0.0
0
LF
HF
HF+TS
LF
HF
TS
LF
HF
HF+TS
the satiety hormone peptide YY
D
C
(PYY) in the plasma of HF diet-inIL-1β
p-IKK
1.4
1.2
β-actin
β-actin
duced obese mice. Peripheral infu1.2
1.0
sion of PYY reduces food intake in
*
1.0
*
0.8
*
rodents (37), and PYY transgenic
0.8
0.6
mice with increased plasma PYY
0.6
0.4
concentrations are protected against
0.4
0.2
0.2
diet-induced obesity (38). In this
0.0
0.0
study, the teasaponin induced inLF
HF+TS
HF
HF+TS
LF
LF
HF
TS
crease in plasma PYY may contribE 1.2
SOCS3
ute to the suppression of food intake
β-actin
and decrease in body weight in HF
1.0
*
*
diet-induced obese mice. The precise
0.8
mechanism by which teasaponin el0.6
evated the plasma concentrations of
0.4
PYY is unclear, however it is known
0.2
that PYY is released from specialized
0.0
enteroendocrine cells called L cells,
LF
HF
HF+TS
predominantly located in the muFigure 6. Effect of chronic teasaponin treatment on the protein levels of inflammatory markers
cosa of the distal gastrointestinal
in the mediobasal hypothalamus of obese mice fed a high-fat (HF) diet for 16 wk. Chronic
(GI) tract (39). A HF diet induces oxtreatment of teasaponin significantly decreased the level of the proinflammatory cytokines TNF-␣
idative GI mucosal injury in rats
(A), IL-6 (B) and IL-1␤ (C), as well as the inflammatory signaling molecules p-IKK (D) and SOCS3
(E). n ⫽ 6 – 8, *P ⬍ .05 vs HF group.
(40), and teasaponin has previously
been shown to have gastroprotective
tified as a target of anti-inflammatory therapy for the effects, where the oral administration of teasaponin pretreatment of obesity-associated type 2 diabetes. Hepato- vented the gastric lesions induced by ethanol in rats (41).
cyte-specific deletion of IKK improved insulin sensitivity Therefore, the prevention of gastric lesions by teasaponin
in mice fed a HF diet (33). The pharmacological inhibition may increase the PYY secretion in the GI tract of HF dietof IKK also prevented liver steatosis in obese mice (34). induced obese mice.
Two types of neurons regulate energy balance in the Arc
Thus, teasaponin represents a novel strategy to suppress
IKK/IB␣ complex mediated responses, and ameliorate of the mediobasal hypothalamus, anorexigenic (POMC)
and orexigenic (NPY/AgRP). Chronic teasaponin treatthe metabolic disorders related to diet-induced obesity.
Dietary teasaponin supplementation (0.5%) for 11 wk ment significantly increased POMC, but not NPY/AgRP
prevented fat accumulation and obesity in mice fed a high- mRNA in the hypothalamic Arc of HF diet-induced obese
fat diet by inhibiting pancreatic lipase activity, thereby mice, implying that teasaponin exerts its anorexigenic acdelaying the intestinal absorption of dietary fat (35). In the tion at least partially by activating the POMC system. It
current study, the chronic ip administration of teasaponin has been reported that peripheral PYY activates anorexdecreased body weight and improved many other obesity- igenic POMC neurons in the hypothalamic Arc. Intraperilinked parameters in mice after fed a HF diet for 16 wk. toneal injection of the truncated form of PYY (PYY3–36)
Furthermore, ip injection of teasaponin suppressed food increased the expression of c-fos in the POMC neurons
intake in the obese mice, consistent with a previous study (42, 43), expression of POMC mRNA (44), and the action
where the oral administration of teasaponin decreased the potential firing rate of POMC neurons in the hypothashort-term feeding response in chicks (36). In addition, we lamic Arc (42). Therefore, the teasaponin-induced infound that suppressing food intake did not elicit malaise, crease in POMC mRNA expression may result from eleTNF-α
β-actin
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body fat and dramatically ameliorated hyperleptinemia induced by
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HF diet-induced obesity. This may
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tral leptin resistance in HF diet-induced obese rodents (2, 47).
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central leptin resistance and im1.0
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paired leptin signaling through
p-STAT3 (47). In contrast, a genetic
0.5
0.5
or pharmacological blockade of in0.0
0.0
flammatory signaling in the hypoSaline
Saline
leptin
SS
SL
TS leptin
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Saline
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thalamus improved leptin sensitivity
p-STAT3
and elevated p-STAT3 (47, 48). In
β-actin
mice with an IKK knockout in hypoFigure 7. Energy intake (EI) at 1, 4 and 24 h after the icv injection of leptin or saline in low-fat
thalamic AgRP neurons, the level of
(LF) diet fed mice (n ⫽ 7– 8) (A), in obese mice fed a high-fat (HF) diet for 8 wk with or without
p-STAT3 was significantly increased
acute treatment of teasaponin (TS, 10 mg/kg ip daily for 2 d) (n ⫽ 7– 8) (B), in obese mice fed a
in response to icv administered leptin
HF diet for 16 wk with or without chronic treatment of teasaponin (10 mg/kg ip daily for 21 d)
(n ⫽ 6 – 8) (C). STAT3 phosphorylation in the mediobasal hypothalamus 1 h after the icv injection
in animals fed a HF diet (47). In this
of leptin or saline in LF diet fed mice (n ⫽ 7– 8) (D) and obese mice fed a HF diet for 16 wk with
study, teasaponin decreased the exor without chronic treatment of teasaponin (n ⫽ 6 – 8) (E). *P ⬍ .05 vs. icv injection of saline
#
pression of the hypothalamic proinwithin the treatment group (LF, HF control, or HF with TS treatment); P ⬍ .05 vs. HF group
(vehicle) with an icv injection of leptin; ⫹P ⬍ .05 vs. HF group (vehicle) with an icv injection of
flammatory cytokines and inflamsaline.
matory signaling molecules, such as
TNF-␣, IL-6, IL-1␤ and p-IKK. This
vated plasma PYY levels. However, Ghamari-Langroudi may have contributed to the improved leptin sensitivity
et al. reported that in an electrophysiological slice study, and hypothalamic leptin signaling via p-STAT3 following
PYY3–36 inhibited the action potential firing activity of the teasaponin treatment in the diet-induced obese mice.
POMC neurons of the arcuate nucleus through the postSOCS3 has been identified as a negative regulator of
synaptic Y2 receptor (45). Therefore, the role of POMC central leptin signaling. The overexpression of SOCS-3
neurons in mediating the anorexigenic response to periph- results in the inhibition of leptin signaling through JAK2/
eral PYY during teasaponin treatment requires further STAT3 (49). Negative feedback in response to excessive
study.
hormone stimulation is a classical mechanism of hormone
Leptin promotes negative energy balance by signaling resistance. It is known that leptin stimulates the expression
in the brain, and the hypothalamus is a key region for the of SOCS3, which directly inhibits leptin signaling in the
control of food intake by this hormone. This negative feed- hypothalamus (50). Furthermore, overexpression of IKK
back loop becomes disrupted in most obese individuals, in the hypothalamic neurons of mice increases SOCS3
resulting in a state known as central leptin resistance. In mRNA expression and protein levels in the hypothalamus
this study we confirmed central leptin resistance in HF diet (47). Therefore in the current study, hyperleptinemia and
induced obese mice. The icv injection of leptin signifi- hypothalamic inflammation in diet-induced obese mice
cantly decreased food intake in LF control mice, but not in may activate a common negative regulator of leptin sigHF obese mice with hyperleptinemia. There are two mech- naling, SOCS3, and contribute to central leptin resistance.
anisms that explain central leptin resistance, hyperleptine- Upregulation of SOCS3 in POMC neurons leads to immia (46) and hypothalamic inflammation (2, 47). Firstly, pairment of STAT3 signaling, with subsequent leptin reit is reported that hyperleptinemia is required for the de- sistance, obesity, and glucose intolerance (51). In contrast,
velopment of leptin resistance in diet-induced obese mice hypothalamic SOCS3-deficient rats exhibited enhanced
(46). In the current study, teasaponin significantly reduced leptin-induced STAT3 activation, decreased body weight
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gain and improved metabolic parameters when exposed to
a high-fat diet (52). In the present study, teasaponin significantly decreased the level of SOCS3 in the hypothalamus of HF induced obese mice, suggesting that SOCS3 is
a potential target for teasaponin’s therapeutic intervention during obesity.
In summary, we have demonstrated that chronic teasaponin treatment significantly reduced food intake and
body weight in HF diet-induced obese mice. Teasaponin
also increased the circulating concentrations of the anorexigenic hormone PYY, and stimulated the expression
of the hypothalamic neuropeptide POMC. Treatment
with teasaponin significantly ameliorated peripheral and
central inflammation by reducing proinflammatory cytokines and inflammatory signaling molecules in the liver,
adipose tissue and hypothalamus. Therefore, teasaponin
has important effects in improving glucose tolerance, central leptin sensitivity and hypothalamic leptin signaling.
These results identify a novel role for teasaponin as an
antiobesity and anti-inflammatory agent.
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